indicated or the offices of the Board of Governors not later than January 26, 2006.

#### A. Federal Reserve Bank of St. Louis (Glenda Wilson, Community Affairs Officer) 411 Locust Street, St. Louis, Missouri 63166-2034:

1. Enterprise Financial Services Corp., Clayton, Missouri; to acquire 100 percent of the voting shares of Clayco Banc Corporation, DeSoto, Kansas, and thereby indirectly acquire Great American Bank, DeSoto, Kansas.

Board of Governors of the Federal Reserve System, December 28, 2006.

#### Jennifer J. Johnson,

Secretary of the Board.

[FR Doc. E6-22532 Filed 1-3-07; 8:45 am]

BILLING CODE 6210-01-S

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

#### Food and Drug Administration

Summaries of Medical and Clinical Pharmacology Reviews of Pediatric Studies; Availability

**AGENCY:** Food and Drug Administration,

HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing the availability of summaries of medical and clinical pharmacology reviews of pediatric studies submitted in supplements for AZOPT (brinzolamide), BETAXON (levobetaxolol), and GLEEVEC (imatinib). These summaries are being made available consistent with the Best Pharmaceuticals for Children Act (the BPCA). For all pediatric supplements submitted under the BPCA, the BPCA requires FDA to make available to the public a summary of the medical and clinical pharmacology reviews of the pediatric studies conducted for the supplement.

ADDRESSES: Submit written requests for single copies of the summaries to the Division of Drug Information (HFD—240), Center for Drug Evaluation and Research, Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857. Please specify by product name which summary or summaries you are requesting. Send one self-addressed adhesive label to assist that office in processing your requests. See the SUPPLEMENTARY INFORMATION section for electronic access to the summaries.

### FOR FURTHER INFORMATION CONTACT:

Grace Carmouze, Center for Drug

Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 22, rm. 6460, Silver Spring, MD 20993–0002, 301–796–0700, e-mail: grace.carmouze@fda.hhs.gov.

#### SUPPLEMENTARY INFORMATION:

#### I. Background

FDA is announcing the availability of summaries of medical and clinical pharmacology reviews of pediatric studies conducted for AZOPT (brinzolamide), BETAXON (levobetaxolol), and GLEEVEC (imatinib). The summaries are being made available consistent with section 9 of the BPCA (Public Law 107-109). Enacted on January 4, 2002, the BPCA reauthorizes, with certain important changes, the pediatric exclusivity program described in section 505A of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 355a). Section 505A of the act permits certain applications to obtain 6 months of marketing exclusivity if, in accordance with the requirements of the statute, the sponsor submits requested information relating to the use of the drug in the pediatric population.

One of the provisions the BPCA added to the pediatric exclusivity program pertains to the dissemination of pediatric information. Specifically, for all pediatric supplements submitted under the BPCA, the BPCA requires FDA to make available to the public a summary of the medical and clinical pharmacology reviews of pediatric studies conducted for the supplement (21 U.S.C. 355a(m)(1)). The summaries are to be made available not later than 180 days after the report on the pediatric study is submitted to FDA (21 U.S.C. 355a(m)(1)). Consistent with this provision of the BPCA, FDA has posted on the Internet at http://www.fda.gov/ cder/pediatric/index.htm summaries of medical and clinical pharmacology reviews of pediatric studies submitted in supplements for AZOPT (brinzolamide), BETAXON (levobetaxolol), and GLEEVEC (imatinib). Copies are also available by mail (see ADDRESSES).

#### II. Electronic Access

Persons with access to the Internet may obtain the document at http://www.fda.gov/cder/pediatric/index.htm.

Dated: December 22, 2006.

#### Jeffrey Shuren,

Assistant Commissioner for Policy.
[FR Doc. E6–22517 Filed 1–3–07; 8:45 am]
BILLING CODE 4160–01–S

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

#### Health Resources and Services Administration

#### National Vaccine Injury Compensation Program; List of Petitions Received

**AGENCY:** Health Resources and Services Administration, HHS.

ACTION: Notice.

**SUMMARY:** The Health Resources and Services Administration (HRSA) is publishing this notice of petitions received under the National Vaccine Injury Compensation Program ("the Program"), as required by Section 2112(b)(2) of the Public Health Service (PHS) Act, as amended. While the Secretary of Health and Human Services is named as the respondent in all proceedings brought by the filing of petitions for compensation under the Program, the United States Court of Federal Claims is charged by statute with responsibility for considering and acting upon the petitions.

FOR FURTHER INFORMATION CONTACT: For information about requirements for filing petitions, and the Program in general, contact the Clerk, United States Court of Federal Claims, 717 Madison Place, NW., Washington, DC 20005, (202) 357–6400. For information on HRSA's role in the Program, contact the Director, National Vaccine Injury Compensation Program, 5600 Fishers Lane, Room 11C–26, Rockville, MD 20857; (301) 443–6593.

SUPPLEMENTARY INFORMATION: The Program provides a system of no-fault compensation for certain individuals who have been injured by specified childhood vaccines. Subtitle 2 of Title XXI of the PHS Act, 42 U.S.C. 300aa-10 et seq., provides that those seeking compensation are to file a petition with the U.S. Court of Federal Claims and to serve a copy of the petition on the Secretary of Health and Human Services, who is named as the respondent in each proceeding. The Secretary has delegated his responsibility under the Program to HRSA. The Court is directed by statute to appoint special masters who take evidence, conduct hearings as appropriate, and make initial decisions as to eligibility for, and amount of, compensation.

A petition may be filed with respect to injuries, disabilities, illnesses, conditions, and deaths resulting from vaccines described in the Vaccine Injury Table (the Table) set forth at Section 2114 of the PHS Act or as set forth at 42 CFR 100.3, as applicable. This Table

lists for each covered childhood vaccine the conditions which may lead to compensation and, for each condition, the time period for occurrence of the first symptom or manifestation of onset or of significant aggravation after vaccine administration. Compensation may also be awarded for conditions not listed in the Table and for conditions that are manifested outside the time periods specified in the Table, but only if the petitioner shows that the condition was caused by one of the listed vaccines.

Section 2112(b)(2) of the PHS Act, 42 U.S.C. 300aa–12(b)(2), requires that the Secretary publish in the **Federal Register** a notice of each petition filed. Set forth below is a list of petitions received by HRSA on July 1, 2006, through September 30, 2006.

Section 2112(b)(2) also provides that the special master "shall afford all interested persons an opportunity to submit relevant, written information"

relating to the following:

- 1. The existence of evidence "that there is not a preponderance of the evidence that the illness, disability, injury, condition, or death described in the petition is due to factors unrelated to the administration of the vaccine described in the petition," and
- 2. Any allegation in a petition that the petitioner either:
- (a) "Sustained, or had significantly aggravated, any illness, disability, injury, or condition not set forth in the Table but which was caused by" one of the vaccines referred to in the Table, or

(b) "Sustained, or had significantly aggravated, any illness, disability, injury, or condition set forth in the Vaccine Injury Table the first symptom or manifestation of the onset or significant aggravation of which did not occur within the time period set forth in the Table but which was caused by a vaccine" referred to in the Table.

This notice will also serve as the special master's invitation to all interested persons to submit written information relevant to the issues described above in the case of the petitions listed below. Any person choosing to do so should file an original and three (3) copies of the information with the Clerk of the U.S. Court of Federal Claims at the address listed above (under the heading FOR FURTHER **INFORMATION CONTACT**), with a copy to HRSA addressed to Director, Division of Vaccine Injury Compensation Program, Healthcare Systems Bureau, 5600 Fishers Lane, Room 11C-26, Rockville, MD 20857. The Court's caption (Petitioner's Name v. Secretary of Health and Human Services) and the docket number assigned to the petition

should be used as the caption for the written submission. Chapter 35 of title 44, United States Code, related to paperwork reduction, does not apply to information required for purposes of carrying out the Program.

#### **List of Petitions**

- Christine Delrio on behalf of Lucas Delrio, Glenwood Springs, Colorado, Court of Federal Claims Number 06–0499V
- Debbra Polley, Moline, Illinois, Court of Federal Claims Number 06– 0500V
- Angelo and Giusseppina Bongiorno on behalf of Anthony Bongiorno, Lake Success, New York, Court of Federal Claims Number 06–0501V
- Karen and John Kellogg on behalf of Brady Kellogg, Boston, Massachusetts, Court of Federal Claims Number 06–0511V
- George N. Lyne on behalf of George B. Lyne, Jr., Deceased, Lindenwold, New Jersey, Court of Federal Claims Number 06–0512V
- Helene and Ralph Haro on behalf of Bailey Nicole Haro, Deceased, Miami, Florida, Court of Federal Claims Number 06–0513V
- Evelyn Willetts and Eugene Stenger on behalf of Ethan Stenger, Philadelphia, Pennsylvania, Court of Federal Claims Number 06– 0516V
- 8. Brian Wasser on behalf of Samuel Wasser, Hyannis, Massachusetts, Court of Federal Claims Number 06–0520V
- Ray Baldonado, Whittier, California, Court of Federal Claims Number 06–0521V
- Robert Veryzer, Clifton Park, New York, Court of Federal Claims Number 06–0522V
- Elizabeth Hatcher on behalf of Michael Farr Hatcher, Cumming, Georgia, Court of Federal Claims Number 06–0526V
- Frank J. Capone, Green Valley, Arizona, Court of Federal Claims Number 06–0529V
- Rose Turner on behalf of Madylyn Gardner, Santa Rosa, California, Court of Federal Claims Number 06–0542V
- 14. Alena Barysiuk and Sachin Sharma on behalf of Lavani Sharma, Castro Valley, California, Court of Federal Claims Number 06–0547V
- 15. Karolina Leszczynski on behalf of Natalie Leszczynski, New York, New York, Court of Federal Claims Number 06–0551V
- Karolina Leszczynski on behalf of Amanda Leszczynski, New York, New York, Court of Federal Claims Number 06–0552V

- 17. Melissa and Matthew Niermann on behalf of Victor Niermann, Lake Success, New York, Court of Federal Claims Number 06–0557V
- Deborah and Jack Breard on behalf of Jack Breard, IV, Lake Success, New York, Court of Federal Claims Number 06–0558V
- 19. Jennifer Ann and Gabriel Gene Rodriguez on behalf of Giavanna Maria Rodriguez, Deceased, Voorheesville, New York, Court of Federal Claims Number 06–0559V
- David Kouri, Boston, Massachusetts, Court of Federal Claims Number 06–0560V
- 21. Jennifer and Patrick Keefe on behalf of Kevin Lucas Keefe, Lake Success, New York Court of Federal Claims Number 06–0565V
- 22. Deborah Friedlander, New York, New York, Court of Federal Claims Number 06–0573V
- Michelle Kristine Staley, Kansas City, Missouri, Court of Federal Claims Number 06–0574V
- 24. Cindy Dudley, Levittown, Pennsylvania, Court of Federal Claims Number 06–0579V
- 25. Cindy Needham and John Ordille on behalf of Thomas Ordille, Somers Point, New Jersey, Court of Federal Claims Number 06–0581V
- 26. Marcia Guy on behalf of Myia Howard, Lemont, Illinois, Court of Federal Claims Number 06–0586V
- 27. Lisa Meunier on behalf of Hannah Meunier, Boston, Massachusetts, Court of Federal Claims Number 06–0588V
- 28. Suzette and David Frear on behalf of Connor David Frear, Newport Beach, California, Court of Federal Claims Number 06–0590V
- Laurel Stiebler, White Bear Lake, Minnesota, Court of Federal Claims Number 06–0591V
- 30. Paris and Allen Golec on behalf of Abigaile Golec, Springdale, Arkansas, Court of Federal Claims Number 06–0595V
- 31. Tiffany Bragdon on behalf of Kayla Bragdon, Peoria, Illinois, Court of Federal Claims Number 06–0597V
- 32. Elihu Sigal, Rancho Mirage, California, Court of Federal Claims Number 06–0600V
- 33. Margaret and Stephen Ricca on behalf of Michael Richard Ricca, Wall, New Jersey, Court of Federal Claims Number 06–0608V
- 34. Veronica Ramirez on behalf of Jeremiah Ramirez, Dallas, Texas, Court of Federal Claims Number 06–0610V
- 35. Kevin Dunn, New Hyde Park, New York, Court of Federal Claims Number 06–0611V
- 36. Christopher Seefeldt on behalf of Maxim Seefeldt, Buffalo, New York,

- Court of Federal Claims Number 06–0618V
- 37. Debbie Squire on behalf of Tyrese Campbell, Philadelphia, Pennsylvania, Court of Federal Claims Number 06–0619V
- 38. Belisario Bolanos, San Bernadino, California, Court of Federal Claims Number 06–0621V
- 39. Janice Ferro, New York, New York, Court of Federal Claims Number 06–0625V
- 40. Jimmie Lee Lazenberry on behalf of Betty Lazenberry, Jacksonville, Florida, Court of Federal Claims Number 06–0630V
- Jimmie Lee Lazenberry on behalf of Henry Lazenberry, Jacksonville, Florida, Court of Federal Claims Number 06–0631V
- 42. Jimmie Lee Lazenberry on behalf of Ricky Lazenberry, Jacksonville, Florida, Court of Federal Claims Number 06–0632V
- 43. Maria Lynch on behalf of Anna Lynch, Vienna, Virginia , Court of Federal Claims Number 06–0634V
- 44. Clair Swaiss, Boston, Massachusetts, Court of Federal Claims Number 06–0638V
- 45. Osama Elgebaly on behalf of Yusra Elgebaly, Boston, Massachusetts, Court of Federal Claims Number 06–0639V
- 46. Julissa and Emiliano Aguero on behalf of Emiliano G. Aguero, Fort Lee, New Jersey, Court of Federal Claims Number 06–0642V
- 47. Stephanie and Clifton Miller on behalf of Kharisa Miller, Boston, Massachusetts, Court of Federal Claims Number 06–0643V
- 48. Nicole Morris on behalf of Grace Morris, Deceased, Morris, Illinois, Court of Federal Claims Number 06–0644V
- Nella and James Coe on behalf of Isabella Coe, Portland, Oregon, Court of Federal Claims Number 06–0645V
- 50. Mirielle Chapa on behalf of Oscar Chapa, Somers Point, New Jersey, Court of Federal Claims Number 06–0647V
- 51. Tiffani Peacock on behalf of Morgan Peacock, Apple Valley, California, Court of Federal Claims Number 06–0649V
- 52. Mitch Anderson, Quincy, Massachusetts, Court of Federal Claims Number 06–0650V
- 53. Christine Saddler on behalf of Daniel Saddler, Eagle River, Alaska, Court of Federal Claims Number 06–0657V
- 54. Rebecca and Gregory Schwartz on behalf of Nathan Schwartz, Birmingham, Alabama, Court of Federal Claims Number 06–0662V

- 55. Bridgette Bigbee and Royce Carter on behalf of Kaleaf Carter, Deceased, Richmond, California, Court of Federal Claims Number 06–0663V
- 56. Douglas Henning, Jacksonville, Florida, Court of Federal Claims Number 06–0665V
- 57. Jennifer Stammer, Edmond, Oklahoma, Court of Federal Claims Number 06–0667V
- Cristal DeBlasis, Philadelphia, Pennsylvania, Court of Federal Claims Number 06–0669V
- Antoinette Chin, Harrington Park, New Jersey, Court of Federal Claims Number 06–0670V
- 60. Melissa and Paul Follett on behalf of Aidan Drakose Exavier Follett, Deceased, Greenville, Michigan, Court of Federal Claims Number 06–0671V
- 61. Christine Bitenieks on behalf of Donovan Bitenieks, Lincoln, Nebraska, Court of Federal Claims Number 06–0673V
- 62. Ana and Hugo Solano on behalf of Allen Solano, Elizabeth, New Jersey, Court of Federal Claims Number 06–0674V
- 63. Tracy Perl on behalf of Andrew Perl, Vienna, Virginia, Court of Federal Claims Number 06–0678V
- 64. Tracy and Brent Dallman on behalf of Luke Dallman, Indianapolis, Indiana, Court of Federal Claims Number 06–0679V

Dated: December 22, 2006.

#### Elizabeth M. Duke,

Administrator.

[FR Doc. E6–22507 Filed 1–3–07; 8:45 am] **BILLING CODE 4165–15–P** 

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

#### **National Institutes of Health**

#### National Center for Research Resources; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which

would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Center for Research Resources Special Emphasis Panel, Wisconsin NPRC.

Date: January 24-26, 2007.

Time: 8 a.m. to 5 p.m.

Agenda: To review and evaluate grant applications.

Place: The Madison Concourse Hotel and Governor's Club, One West Dayton Street, Madison, WI 53703.

Contact Person: Carol Lambert, PhD, Scientific Review Administrator, Office of Review, National Center For Research Resources, National Institutes of Health, 6701 Democracy Blvd. 1 Dem. Plaza, Room 1076, Bethesda, MD 20892, (301) 435–0814, lambert@mail.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine, 93.333, Clinical Research; 93.371, Biomedical Technology; 93.389, Research Infrastructure, 93.306, 93.333, National Institutes of Health, HHS)

Dated: December 26, 2006.

#### Anna Snouffer,

Acting Director, Office of Federal Advisory Committee Policy.

[FR Doc. 06–9971 Filed 1–3–07; 8:45 am] BILLING CODE 4140–01–M

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

#### **National Institutes of Health**

# National Institute of Allergy and Infectious Diseases, Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings.

The meeting will be closed to the public in accordance with the provisions set forth in section 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel, Cooperative Research Patnerships for Influenza Product Development.

Date: January 24–25, 2007.

Time: 8 a.m. to 5 p.m.

Agenda: To review and evaluate grant applications.

*Place:* Hilton Silver Spring, 8727 Colesville Road, Silver Spring, MD 20910.